TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava.

As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year.  

TAVI en insuficiencia aórtica pura

This study looked into PARTNER 3 patient health status at 1, 6 and 12 months after procedure with the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36 and EQ-5D.

Primary end point (PFP) were changes in KCCQ-Overall Summary (KCCQ-OS) over time.

At 30 days, TAVR was associated to better health status (a 16-point difference in KCCQ-OS vs. SAVR (p<0.001).


Read also: Major Bleeding in Patients with Aspirin Plus Rivaroxaban.


At 6 and 12 months, TAVR also presented better health status, but the effect saw a reduction over time (KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both). In addition, TAVR showed more patients with excellent evolution (alive and with KCCQ-OS ≥ 75) at 6 months (90.3% vs. 85.3%; p=0.03) and at 12 months (87.3% vs. 82.8%; p=0.07). 

Conclusion

Low-risk patients with severe aortic stenosis undergoing TAVR were associated with significantly better early and late health compared against SAVR. 

Courtesy of Dr. Carlos Fava.

Original Title: Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis.

Reference: Suzanne J. Baron, et al. J Am Coll Cardiol Article in press.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...